Telomir Pharmaceuticals Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Public

  • Employees
  • 2

Employees

  • Stock Symbol
  • TELO

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $0.35
  • (As of Friday Closing)

Telomir Pharmaceuticals General Information

Description

Telomir Pharmaceuticals Inc is a preclinical-stage biotechnology company focused on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases rather than treating symptoms alone. The company's research targets fundamental cellular processes associated with disease progression and functional decline, including metal-ion dysregulation, oxidative stress, epigenetic regulation, mitochondrial dysfunction, and telomere integrity. Telomir's investigational compound, Telomir-1 (Zn-Telomir), is a novel orally administered small molecule engineered to modulate intracellular metal balance particularly iron, copper, calcium, and zinc.

Contact Information

Formerly Known As
Metallo Therapies
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 100 South East 2nd Street
  • Suite 2000 #1009
  • Miami, FL 33131
  • United States
+1 (786)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 100 South East 2nd Street
  • Suite 2000 #1009
  • Miami, FL 33131
  • United States
+1 (786)

Telomir Pharmaceuticals Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Telomir Pharmaceuticals Stock Performance

As of 20-Nov-2026, Telomir Pharmaceuticals’s stock price is $0.35. Its current market cap is $26.8M with 73.7M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.35 $0.44 $0.35 - $1.58 $26.8M 73.7M 125K -$0.96

Telomir Pharmaceuticals Financials Summary

As of 30-Sep-2026, Telomir Pharmaceuticals has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 77,360 38,397 121,746
Revenue 0 0 0 0
EBITDA (5,686) (10,539) (12,242) (11,429)
Net Income (5,479) (10,413) (16,533) (13,072)
Total Assets 4,641 7,341 1,324 4,774
Total Debt 0 0 0 101
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Telomir Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Telomir Pharmaceuticals‘s full profile, request access.

Request a free trial

Telomir Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Telomir Pharmaceuticals Inc is a preclinical-stage biotechnology company focused on the development of small-molecule th
Drug Discovery
Miami, FL
2 As of 2025

Palma de Mallorca, Spain
 

Plymouth Meeting, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Telomir Pharmaceuticals Competitors (7)

One of Telomir Pharmaceuticals’s 7 competitors is Laminar Pharma, a Venture Capital-Backed company based in Palma de Mallorca, Spain.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Laminar Pharma Venture Capital-Backed Palma de Mallorca, Spain
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Celprogen Private Debt Financed Torrance, CA
Stempeutics Venture Capital-Backed Bangalore, India
Touchlight Venture Capital-Backed Hampton, United Kingdom
You’re viewing 5 of 7 competitors. Get the full list »

Telomir Pharmaceuticals Patents

Telomir Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2022082079-A1 Metalloenzyme inhibitors for treating cancers, alzheimer's disease, hemochromatosis, and other disorders Inactive 16-Oct-2020

Telomir Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Telomir Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Telomir Pharmaceuticals‘s full profile, request access.

Request a free trial

Telomir Pharmaceuticals Acquisitions (1)

Telomir Pharmaceuticals’s most recent deal was a Merger/Acquisition with TELI Pharmaceuticals for . The deal was made on 22-Apr-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
TELI Pharmaceuticals 22-Apr-2026 Merger/Acquisition Pharmaceuticals
To view Telomir Pharmaceuticals’s complete acquisitions history, request access »

Telomir Pharmaceuticals ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Telomir Pharmaceuticals’s complete esg history, request access »

Telomir Pharmaceuticals FAQs

  • When was Telomir Pharmaceuticals founded?

    Telomir Pharmaceuticals was founded in 2021.

  • Where is Telomir Pharmaceuticals headquartered?

    Telomir Pharmaceuticals is headquartered in Miami, FL.

  • What is the size of Telomir Pharmaceuticals?

    Telomir Pharmaceuticals has 2 total employees.

  • What industry is Telomir Pharmaceuticals in?

    Telomir Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Telomir Pharmaceuticals a private or public company?

    Telomir Pharmaceuticals is a Public company.

  • What is Telomir Pharmaceuticals’s stock symbol?

    The ticker symbol for Telomir Pharmaceuticals is TELO.

  • What is the current stock price of Telomir Pharmaceuticals?

    As of 20-Nov-2026 the stock price of Telomir Pharmaceuticals is $0.35.

  • What is the current market cap of Telomir Pharmaceuticals?

    The current market capitalization of Telomir Pharmaceuticals is $26.8M.

  • Who are Telomir Pharmaceuticals’s competitors?

    Laminar Pharma, Inovio Pharmaceuticals, Celprogen, Stempeutics, and Touchlight are some of the 7 competitors of Telomir Pharmaceuticals.

  • What is Telomir Pharmaceuticals’s annual earnings per share (EPS)?

    Telomir Pharmaceuticals’s EPS for 12 months was -$0.96.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process